Evidence map›Paper›PMID 28261636›Full record

ArticleGraphene technology2016

Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.

Shruti Kanakia, Jimmy Toussaint, Praveen Kukarni, Stephen Lee, Sayan Mullick Chowdhury, Slah Khan, Sandeep K Mallipattu, Kenneth R Shroyer, William Moore, Balaji Sitharaman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Graphene technology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shruti KanakiaDepartment of Biomedical Engineering, Northeastern University, Boston, MA, USA.
Jimmy ToussaintDepartment of Biomedical Engineering, Northeastern University, Boston, MA, USA.
Praveen KukarniCenter for Translational Neuroimaging, Northeastern University, Boston, MA, USA.
Stephen LeeDepartment of Biomedical Engineering, Northeastern University, Boston, MA, USA.
Sayan Mullick ChowdhuryDepartment of Biomedical Engineering, Northeastern University, Boston, MA, USA.
Slah KhanDepartment of Biomedical Engineering, Northeastern University, Boston, MA, USA.
Sandeep K MallipattuDivision of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
Kenneth R ShroyerDepartment of Pathology, Stony Brook University, Stony Brook, NY, USA.
William MooreDepartment of Radiology, Stony Brook University, Stony Brook, NY, USA.
Balaji SitharamanDepartment of Biomedical Engineering, Northeastern University, Boston, MA, USA.
Northeastern University · USStony Brook University · US

Funding

Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent For Diagnosis of Renal FailureR44DK100205 · NIDDK · THERAGNOSTIC TECHNOLOGIES, INC. · PI SITHARAMAN, BALAJI, TOUSSAINT, JIMMY DEON · 2015 to 2016
$1.5M
The Role of KLF15 as a transcriptional regulator of podocyte differentiationK08DK102519 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI MALLIPATTU, SANDEEP K · 2014 to 2018
$917k
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based MagnetiR41DK100205 · NIDDK · THERAGNOSTIC TECHNOLOGIES, INC. · PI SITHARAMAN, BALAJI · 2013 to 2013
$160k
NIDDK NIH HHS K08 DK102519NIDDK NIH HHS R41 DK100205NIDDK NIH HHS R44 DK100205
6 · The paper itself

Abstract

The etiology of renal insufficiency includes primary (e.g polycystic kidney disease) or secondary (e.g. contrast media, diabetes) causes. The regulatory restrictions placed on the use of contrast agents (CAs) for non-invasive imaging modalities such as X-ray computed tomography (CT) and magnetic resonance imaging (MRI) affects the clinical management of these patients. With the goal to develop a next-generation CA for unfettered use for renal MRI, here we report, in a rodent model of chronic kidney disease, the preclinical safety and efficacy of a novel nanoparticle CA comprising of manganese (Mn

Indexed as

Chronic Kidney DiseaseContrast AgentGadoliniumMagnetic Resonance ImagingMangradexNephrogenic Systemic Fibrosis

Identifiers

PMID28261636
PMCPMC5333926
OpenAlexW2496731774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.